In August 2009, Novartis narrowed the extent of its earlier 2008 Trademark application to an exclusive right to use the term Opaxio with regard to oncology (cancer drugs), as opposed to their broader 2008 application. This means that they wanted to "tighten up" their exclusive rights to use the Trademark in dealing with cancer treatment. IMNSHO, as a business owner with a good deal of Trademark experience, no one bothers to narrow their application unless they intend to actually USE the trademark - and relatively soon. NOVARTIS intends to market this drug, you can be sure of that. The investors who ponied up $30 Million within the last month are aware of this. This stock has legs.